33 results
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
by such tax returns (whether or not such amounts are shown as due on any tax return), (B) no deficiency assessment with respect to a proposed adjustment
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
of Aβ monomers and a positive trend on cognitive function as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog … as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog, in patients receiving CT1812 compared to placebo. We anticipate
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
function as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog, in patients receiving CT1812 compared to placebo. We … Assessment Scale-Cognitive Subscale, or ADAS-Cog, in patients receiving CT1812 compared to placebo. We anticipate completing enrollment in 2023 with top
424B4
cwrsn3wquotheybp5bvv
8 Jan 24
Prospectus supplement with pricing info
4:11pm
8-K
EX-10.1
fazjg2jt6dz o8
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
S-3
icn69l36ki9evv
23 Dec 22
Shelf registration
4:16pm
S-3
EX-1.2
xu8nq37 8cuqxc07hwye
23 Dec 22
Shelf registration
4:16pm
8-K
EX-1.1
94cl1dift lbihw
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
q6j975if3efj5
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
sn7t9p
20 Oct 22
Draft registration statement
12:00am
8-K
EX-99.1
02mhom1 9l32vzfu7
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am
8-K
EX-99.1
ibm0emb2qfk7g5f 79q7
16 Jun 22
Regulation FD Disclosure
7:08am
DEF 14A
iuam5reb6x5pof
25 Apr 22
Definitive proxy
5:28pm